CNTB - Connect Biopharma says atopic dermatitis study for lead asset met main goal

Connect Biopharma (NASDAQ:CNTB) announced that its lead candidate CBP-201 met the primary efficacy endpoint in a Phase 2 study involving adults with moderate-to-severe atopic dermatitis (AD). Connect (CNTB) shares are trading ~22.4% lower in the post-market. Based on a scale measuring the disease progression called Eczema Area and Severity Index (EASI), the 226-patient placebo-controlled study achieved the primary efficacy endpoint with statistical significance. Across all three study arms at 300mg Q2W, 150mg Q2W, or 300mg every four weeks (Q4W), the EASI scores were statistically superior to placebo from baseline to Week 16. In the CBP-201 300mg Q2W arm, the treatment was better than the placebo across other key secondary efficacy endpoints too. There was a favorable safety profile for the subcutaneously administered drug with a similar incidence of side effects leading to study drug discontinuation across treatment and placebo arms. A Phase 3 trial is expected to begin in mid-2022.

For further details see:

Connect Biopharma says atopic dermatitis study for lead asset met main goal